241 results
8-K
EX-99.1
INSM
Insmed Incorporated
8 Aug 24
Insmed Reports Second-Quarter 2024 Financial Results and Provides Business Update
7:00am
in the healthcare community; our inability to obtain and maintain adequate reimbursement from government or third-party payors for ARIKAYCE or, if approved … or implementing new technology; risk that we are unable to maintain our significant customers; risk that government healthcare reform materially increases our
8-K
EX-99.1
INSM
Insmed Incorporated
3 Jul 24
Regulation FD Disclosure
9:00am
in the degree of market acceptance of brensocatib by physicians, patients, third-party payors and others in the healthcare community; inaccuracies
8-K
EX-99.2
INSM
Insmed Incorporated
3 Jul 24
Regulation FD Disclosure
9:00am
and others in the healthcare community; inaccuracies in the Company's estimates of the size of the potential markets for brensocatib or in data the Company has
8-K
EX-99.1
INSM
Insmed Incorporated
4 Jun 24
Regulation FD Disclosure
7:00am
, brensocatib or TPIP by physicians, patients, third-party payors and others in the healthcare community; failure to continue to successfully … personnel or to effectively manage our growth; risk that government healthcare reform materially increases our costs and damages our financial condition
8-K
EX-1.1
8060qxdx0rozderikv0b
30 May 24
Insmed Announces Proposed $500 Million Public Offering of Common Stock
5:32pm
8-K
EX-99.2
sc6bzugq
30 May 24
Insmed Announces Proposed $500 Million Public Offering of Common Stock
5:32pm
8-K
EX-99.2
ui77 su37z
30 May 24
Insmed Announces Proposed $500 Million Public Offering of Common Stock
5:32pm
424B5
uvct 83flvdgc4870
30 May 24
Prospectus supplement for primary offering
4:02pm
424B5
qk5o4e0yacp2dx b1
28 May 24
Prospectus supplement for primary offering
7:14pm
8-K
psam4cen dq2q
28 May 24
Insmed Announces Positive Topline Results from Landmark ASPEN Study of Brensocatib in Patients with Bronchiectasis
6:30am
8-K
EX-99.2
0gu9rjbm6av4zr7bx
28 May 24
Insmed Announces Positive Topline Results from Landmark ASPEN Study of Brensocatib in Patients with Bronchiectasis
6:30am
8-K
EX-99.1
x9yv49a0r1k a0lkx2
28 May 24
Insmed Announces Positive Topline Results from Landmark ASPEN Study of Brensocatib in Patients with Bronchiectasis
6:30am
8-K
EX-99.1
2hl2wgi3pz x7we2p
9 May 24
Insmed Reports First-Quarter 2024 Financial Results and Provides Business Update
7:05am
8-K
EX-10.1
5mijck98s18rt ivp0u
22 Feb 24
Insmed Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides Business Update
7:58am
8-K
EX-99.1
oadb0148
22 Feb 24
Insmed Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides Business Update
7:58am
424B5
ebje3h tbi9
22 Feb 24
Prospectus supplement for primary offering
7:43am